Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akurit-4 + Akurit-3
- Development stage
- Phase 4
- Lead developer
- Lupin
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Akurit-4 + Akurit-3 is a sequential combination regimen of two fixed-dose combination (FDC) products developed by Lupin Ltd. for the treatment of tuberculosis caused by *Mycobacterium tuberculosis*. Akurit-4 is used during the intensive phase of treatment and contains four first-line anti-tuberculosis drugs: rifampicin (which inhibits bacterial DNA-dependent RNA polymerase), isoniazid (which inhibits mycolic acid synthesis), pyrazinamide (which disrupts membrane potential and targets aspartate decarboxylase PanD), and ethambutol (which inhibits arabinosyltransferases). Akurit-3 is used during the continuation phase and contains rifampicin, isoniazid, and ethambutol, omitting pyrazinamide to reduce toxicity (such as hyperuricemia) while maintaining bacteriological control. This sequential regimen simplifies therapy, improves patient adherence, and helps prevent the development of drug-resistant tuberculosis strains.
- Other names
- Akurit-3 + Akurit-4Akurit-4/Akurit-3
02
Targets
embA (Arabinosyltransferase A)embB (Arabinosyltransferase EmbB)EmbC (Mycobacterium avium complex arabinosyltransferase EmbC)rpoB (DNA-directed RNA polymerase subunit beta)InhAAspartate decarboxylase
Beyond the preview
Go deeper on Akurit-4 + Akurit-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akurit-4 + Akurit-3.